Abstract | BACKGROUND:
Tacrolimus ( FK 506), a metabolite of the fungus Streptomyces tsukubaensis, is an anti-T-cell drug. It acts by inhibiting the production of IL-2, IL-3, IL-4, TNFa, and GM-CSF. More potent and with slightly less secondary effects than cyclosporine, it has been the object of considerable interest, especially in conditions that could benefit from the latter. OBJECTIVE: CONCLUSIONS:
|
Authors | Q H Dé Tran, E Guay, S Chartier, J Tousignant |
Journal | Journal of cutaneous medicine and surgery
(J Cutan Med Surg)
2001 Jul-Aug
Vol. 5
Issue 4
Pg. 329-35
ISSN: 1203-4754 [Print] United States |
PMID | 11907845
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Immunosuppressive Agents
- Placebos
- Tacrolimus
|
Topics |
- Administration, Oral
- Administration, Topical
- Adult
- Animals
- Behcet Syndrome
(drug therapy)
- Child
- Clinical Trials as Topic
- Cricetinae
- Dermatitis, Atopic
(drug therapy)
- Dermatitis, Contact
(drug therapy)
- Double-Blind Method
- Hair
(drug effects, growth & development)
- Humans
- Immunosuppressive Agents
(administration & dosage, pharmacology, therapeutic use)
- Lupus Erythematosus, Cutaneous
(drug therapy)
- Mice
- Placebos
- Psoriasis
(drug therapy)
- Pyoderma Gangrenosum
(drug therapy)
- Randomized Controlled Trials as Topic
- Rats
- Sezary Syndrome
(drug therapy)
- Skin Diseases
(drug therapy)
- Skin Neoplasms
(drug therapy)
- Skin Transplantation
- Tacrolimus
(administration & dosage, pharmacology, therapeutic use)
- Time Factors
|